Jatamansin

Jatamansin

SCHEMBL30634819

CC=C(C)C(=O)OC1Cc2c(ccc3ccc(=O)oc23)OC1(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 15/20 1.00
▸ HPGD P15428 12/20 1.00
▸ CYP3A4 P08684 3/20 1.00
▸ HSD17B10 Q99714 3/20 1.00
▸ ALDH1A1 P00352 13/20 0.62
▸ MAPT P10636 3/20 0.62
▸ HTT P42858 3/20 0.61
▸ LMNA P02545 2/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ RCE1 Q9Y256 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ ABCB1 P08183 1/20 0.61
▸ TP53 P04637 2/20 0.60
▸ POLB P06746 2/20 0.60
▸ GAA P10253 2/20 0.60
▸ NPY1R P25929 1/20 0.49
▸ NPY2R P49146 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Jatamansin SCHEMBL26671050 1.00 KDM4E (1.00) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Jatamansin SCHEMBL29385603 1.00 KDM4E (1.00) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Jatamansin SCHEMBL12062120 1.00 KDM4E (1.00) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Jatamansin SCHEMBL14523891 1.00 KDM4E (1.00) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
SCHEMBL31349688 0.90 KDM4E (0.81) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
SCHEMBL29707867 0.86 KDM4E (0.76) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Decursinol Angelate SCHEMBL14310264 0.79 MAOA (0.76) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Decursinol Angelate SCHEMBL3901157 0.79 MAOA (0.76) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Decursinol Angelate SCHEMBL4740622 0.79 MAOA (0.76) KDM4EHPGDCYP3A4HSD17B10ALDH1A1
Decursinol Angelate SCHEMBL3901154 0.79 MAOA (0.76) KDM4EHPGDCYP3A4HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724079-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Stealth BioTherapeutics Inc. (US) 2026-04-15 — — EP claimed
EP-4719404-A2 METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE Stealth BioTherapeutics Inc. (US) 2026-04-08 — — EP claimed
EP-4533059-A1 ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE Stealth BioTherapeutics Inc. (US) 2025-04-09 — — EP claimed
WO-2024254164-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION STEALTH BIOTHERAPEUTICS INC. (US) 2024-12-12 — — WO claimed
WO-2024243490-A2 METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE STEALTH BIOTHERAPEUTICS INC. (US) 2024-11-28 — — WO claimed
WO-2023230322-A1 ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE STEALTH BIOTHERAPEUTICS INC. (US) 2023-11-30 — — WO claimed
EP-4724079-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Stealth BioTherapeutics Inc. (US) 2026-04-15 — — EP disclosed
EP-4719404-A2 METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE Stealth BioTherapeutics Inc. (US) 2026-04-08 — — EP disclosed
EP-4533059-A1 ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE Stealth BioTherapeutics Inc. (US) 2025-04-09 — — EP disclosed
WO-2024254164-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION STEALTH BIOTHERAPEUTICS INC. (US) 2024-12-12 — — WO disclosed
WO-2024243490-A2 METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE STEALTH BIOTHERAPEUTICS INC. (US) 2024-11-28 — — WO disclosed
WO-2023230322-A1 ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE STEALTH BIOTHERAPEUTICS INC. (US) 2023-11-30 — — WO disclosed
Send feedback